Biohaven Ltd. (NYSE:BHVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Biohaven Ltd. (NYSE:BHVN) have received an average rating of “Moderate Buy” from the seventeen research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $22.2667.

A number of brokerages have recently issued reports on BHVN. Wall Street Zen lowered shares of Biohaven from a “sell” rating to a “strong sell” rating in a research note on Sunday, April 26th. Raymond James Financial reiterated a “strong-buy” rating on shares of Biohaven in a research note on Wednesday, May 27th. Citigroup boosted their price target on shares of Biohaven from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. The Goldman Sachs Group upgraded shares of Biohaven to a “strong-buy” rating in a research note on Friday, February 6th. Finally, Morgan Stanley dropped their price target on shares of Biohaven from $21.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th.

Biohaven Price Performance

Shares of NYSE:BHVN opened at $11.37 on Friday. The company has a 50-day simple moving average of $9.70 and a 200-day simple moving average of $10.43. Biohaven has a one year low of $7.48 and a one year high of $18.57. The company has a debt-to-equity ratio of 1.87, a quick ratio of 7.41 and a current ratio of 7.41. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -2.01 and a beta of 1.35.

Biohaven (NYSE:BHVN) last announced its earnings results on Monday, May 4th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). On average, analysts predict that Biohaven will post -3.01 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BHVN. Janus Henderson Group PLC increased its stake in shares of Biohaven by 1,145.9% during the first quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock worth $148,214,000 after acquiring an additional 16,127,247 shares during the period. Suvretta Capital Management LLC boosted its holdings in Biohaven by 83.0% during the fourth quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock worth $116,140,000 after buying an additional 4,666,666 shares in the last quarter. Infinitum Asset Management LLC boosted its holdings in Biohaven by 267.6% during the fourth quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company’s stock worth $70,562,000 after buying an additional 4,550,000 shares in the last quarter. Stifel Financial Corp boosted its holdings in Biohaven by 50.3% during the fourth quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock worth $112,221,000 after buying an additional 3,328,506 shares in the last quarter. Finally, Stempoint Capital LP purchased a new stake in Biohaven during the first quarter worth about $13,489,000. 88.78% of the stock is currently owned by institutional investors and hedge funds.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.